Quantcast

Industry news that matters to you.  Learn more

Archives for April 2012

New Fnding Increases Chances of Rapid Detection and Targeted Treatment

Men with a faulty gene known to increase the risk of breast cancer in women are four times more likely to develop prostate cancer, important new research published in the British Journal of Cancer shows.

Denator-led Research Project Aims to Develop New Biomarker Discovery Platform for Cancer Diagnostics

Denator AB announced today a joint research project, together with Erasmus Medical Center and Amsterdam Medical Center, which will be sponsored by the EU Eurostars program. Aimed at developing a unique new biomarker discovery platform for cancer diagnostics, the project was ranked 3rd out of almost 300 European project applications.

Novo Nordisk and Oxford University Team Up to Develop Novel Treatments for Rheumatoid Arthritis and Other Inflammatory Diseases

Today, Novo Nordisk and the Kennedy Institute of Rheumatology at Oxford University jointly announced a new partnership to develop promising new drug candidates and identify novel biomarkers and treatment targets for rheumatoid arthritis and other autoimmune inflammatory diseases.

Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDI’s Planned Offering of Personalized Medicine Clinical Diagnostic Services

Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI”) and Target Discovery, Inc. (“TDI”), (together “the companies”), today announced the signing of expanded strategic technology license and supply agreements (the “Agreements”). Under these agreements, TDI now has the right to use PBI’s patented and enabling Pressure Cycling Technology (“PCT”) Platform for their planned entry into the clinical diagnostics testing market. The planned commercial diagnostic services will initially target what the companies believe are critical, unmet needs in treatment selection guidance for ovarian cancer. Until now, PBI’s PCT Platform has been available on a “research-use-only” basis.

New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer

Veridex, LLC announced today that it has joined with Novartis Pharmaceuticals Corporation in an educational alliance to encourage and facilitate research involving circulating tumor cells, or CTCs, as a potential biomarker in metastatic prostate cancer.